Clinical efficacy of Xuebijing injection for the treatment of sepsis: A retrospective cohort study

IF 4.2 2区医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE

Journal of Integrative Medicine-Jim Pub Date : 2024-11-01 DOI:10.1016/j.joim.2024.08.006

Zhao-tang Gong , Hong-xin Yang , Ben-ben Zhu , Huan-huan Liu , Guleng Siri

{"title":"Clinical efficacy of Xuebijing injection for the treatment of sepsis: A retrospective cohort study","authors":"Zhao-tang Gong , Hong-xin Yang , Ben-ben Zhu , Huan-huan Liu , Guleng Siri","doi":"10.1016/j.joim.2024.08.006","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>The objective of this study was to investigate the clinical efficacy and safety of treating sepsis patients with Xuebijing injection (XBJI).</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of 418 patients who experienced severe infections and were treated with XBJI from June 2018 to June 2021. Propensity score matching was used to match the patient cases. The study population included 209 pairs of cases (418 individuals), and the analysis included data from before and after a 14-day course of treatment with carbapenem alone, or carbapenem with XBJI.</div></div><div><h3>Results</h3><div>There were no significant differences in the 14-day mortality or length of hospital stay (<em>P</em> > 0.05) between the two groups. The combined treatment group had more patients with C-reactive protein that returned to normal levels (compared to baseline) than the non-combined treatment group (14.4% <em>vs</em> 8.1%; odds ratio [OR]: 0.528; 95% confidence interval [CI]: 0.282–0.991; <em>P</em> = 0.026). Similarly, the combined treatment group had higher procalcitonin attainment rate (55.0% <em>vs</em> 39.7%; OR: 0.513; 95% CI: 0.346–0.759; <em>P</em> = 0.001) than the non-combined treatment group. Further, more patients in the combined treatment group achieved normal creatinine levels than in the non-combined treatment group (64.1% <em>vs</em> 54.1%; OR: 0.659; 95% CI: 0.445–0.975; <em>P</em> = 0.037).</div></div><div><h3>Conclusion</h3><div>The combination of XBJI with carbapenem did not reduce the 14-day mortality rate of patients with severe infection, but it was able to reduce the level of inflammatory factors in patients with sepsis, and had a protective effect on liver and kidney function.</div><div><br>Please cite this article as: Gong ZT, Yang HX, Zhu BB, Liu HH, Siri GL. Clinical efficacy of Xuebijing injection for the treatment of sepsis: A retrospective cohort study. <em>J Integr Med.</em> 2024; 22(6): 645–651.</div></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"22 6","pages":"Pages 645-651"},"PeriodicalIF":4.2000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Integrative Medicine-Jim","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2095496424003765","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

The objective of this study was to investigate the clinical efficacy and safety of treating sepsis patients with Xuebijing injection (XBJI).

Methods

We conducted a retrospective analysis of 418 patients who experienced severe infections and were treated with XBJI from June 2018 to June 2021. Propensity score matching was used to match the patient cases. The study population included 209 pairs of cases (418 individuals), and the analysis included data from before and after a 14-day course of treatment with carbapenem alone, or carbapenem with XBJI.

Results

There were no significant differences in the 14-day mortality or length of hospital stay (P > 0.05) between the two groups. The combined treatment group had more patients with C-reactive protein that returned to normal levels (compared to baseline) than the non-combined treatment group (14.4% vs 8.1%; odds ratio [OR]: 0.528; 95% confidence interval [CI]: 0.282–0.991; P = 0.026). Similarly, the combined treatment group had higher procalcitonin attainment rate (55.0% vs 39.7%; OR: 0.513; 95% CI: 0.346–0.759; P = 0.001) than the non-combined treatment group. Further, more patients in the combined treatment group achieved normal creatinine levels than in the non-combined treatment group (64.1% vs 54.1%; OR: 0.659; 95% CI: 0.445–0.975; P = 0.037).

Conclusion

The combination of XBJI with carbapenem did not reduce the 14-day mortality rate of patients with severe infection, but it was able to reduce the level of inflammatory factors in patients with sepsis, and had a protective effect on liver and kidney function.

Please cite this article as: Gong ZT, Yang HX, Zhu BB, Liu HH, Siri GL. Clinical efficacy of Xuebijing injection for the treatment of sepsis: A retrospective cohort study. J Integr Med. 2024; 22(6): 645–651.

查看原文本刊更多论文

雪碧注射液治疗败血症的临床疗效：回顾性队列研究。

方法我们对2018年6月至2021年6月期间经历严重感染并接受雪碧注射液治疗的418例患者进行了回顾性分析。采用倾向得分匹配法对患者病例进行匹配。研究人群包括 209 对病例（418 人），分析包括单独使用碳青霉烯类药物或碳青霉烯类药物联合 XBJI 治疗 14 天疗程前后的数据。结果两组患者的 14 天死亡率或住院时间无显著差异（P > 0.05）。与非联合治疗组相比，联合治疗组有更多患者的 C 反应蛋白恢复到正常水平（与基线相比）（14.4% vs 8.1%；几率比 [OR]：0.528; 95% confidence interval [CI]：0.282-0.991; P = 0.026).同样，与非联合治疗组相比，联合治疗组的降钙素原达标率更高（55.0% vs 39.7%；OR：0.513；95% CI：0.346-0.759；P = 0.001）。结论XBJI与碳青霉烯类药物联合治疗并不能降低重症感染患者的14天死亡率，但能降低脓毒症患者的炎症因子水平，并对肝肾功能有保护作用。本文引用如前Gong ZT, Yang HX, Zhu BB, Liu HH, Siri GL.雪碧注射液治疗败血症的临床疗效：一项回顾性队列研究。J Integr Med.2024; Epub ahead of print.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Integrative Medicine-Jim Medicine-Complementary and Alternative Medicine

CiteScore

9.20

自引率

4.20%

发文量

3319

期刊介绍： The predecessor of JIM is the Journal of Chinese Integrative Medicine (Zhong Xi Yi Jie He Xue Bao). With this new, English-language publication, we are committed to make JIM an international platform for publishing high-quality papers on complementary and alternative medicine (CAM) and an open forum in which the different professions and international scholarly communities can exchange views, share research and their clinical experience, discuss CAM education, and confer about issues and problems in our various disciplines and in CAM as a whole in order to promote integrative medicine. JIM is indexed/abstracted in: MEDLINE/PubMed, ScienceDirect, Emerging Sources Citation Index (ESCI), Scopus, Embase, Chemical Abstracts (CA), CAB Abstracts, EBSCO, WPRIM, JST China, Chinese Science Citation Database (CSCD), and China National Knowledge Infrastructure (CNKI). JIM Editorial Office uses ThomsonReuters ScholarOne Manuscripts as submitting and review system (submission link: http://mc03.manuscriptcentral.com/jcim-en). JIM is published bimonthly. Manuscripts submitted to JIM should be written in English. Article types include but are not limited to randomized controlled and pragmatic trials, translational and patient-centered effectiveness outcome studies, case series and reports, clinical trial protocols, preclinical and basic science studies, systematic reviews and meta-analyses, papers on methodology and CAM history or education, conference proceedings, editorials, commentaries, short communications, book reviews, and letters to the editor. Our purpose is to publish a prestigious international journal for studies in integrative medicine. To achieve this aim, we seek to publish high-quality papers on any aspects of integrative medicine, such as acupuncture and traditional Chinese medicine, Ayurveda medicine, herbal medicine, homeopathy, nutrition, chiropractic, mind-body medicine, taichi, qigong, meditation, and any other modalities of CAM; our commitment to international scope ensures that research and progress from all regions of the world are widely covered. These ensure that articles published in JIM have the maximum exposure to the international scholarly community. JIM can help its authors let their papers reach the widest possible range of readers, and let all those who share an interest in their research field be concerned with their study.